<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on September 12, 2012</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT00696436</url>
  </required_header>
  <id_info>
    <org_study_id>01-06-TL-491-019</org_study_id>
    <secondary_id>U1111-1113-9161</secondary_id>
    <nct_id>NCT00696436</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda Global Research &amp; Development Center, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda Global Research &amp; Development Center, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil,
      once daily (QD), compared to placebo, valsartan and olmesartan in participants with
      essential hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension affects approximately 50 million individuals in the United States. As the
      population ages, the prevalence of hypertension will continue to increase if broad and
      effective preventive measures are not implemented. According to the World Health
      Organization, hypertension is the most common attributable cause of preventable death in
      developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular
      disease, cerebrovascular disease, and renal failure. Despite the availability of
      antihypertensive treatments, hypertension remains inadequately controlled: only about
      one-third of patients successfully maintain control.

      A major component of blood pressure regulation is the renin-angiotensin-aldosterone system.
      This is a system of hormone-mediated feedback interactions that result in the relaxation or
      constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide
      hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting
      enzyme as part of the renin-angiotensin-aldosterone system. Angiotensin II is the principal
      pressor agent of the renin-angiotensin-aldosterone system and has multiple effects on the
      cardiovascular system and on electrolyte homeostasis.

      TAK-491 (azilsartan medoxomil) is an angiotensin II type 1 receptor antagonist currently
      being tested as a treatment for essential hypertension.

      Study participation is anticipated to be about 10 weeks. Multiple procedures will occur at
      each visit which may include fasting, blood collection, urine collection, physical
      examinations, electrocardiograms and ambulatory blood pressure monitoring. Outside of the
      study center, participants will be required wear an ambulatory blood pressure monitoring
      device at 24 hour intervals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response</measure>
    <time_frame>Baseline and Week 6.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1291</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Azilsartan Medoxomil 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan Medoxomil 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 320 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan 40 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil</intervention_name>
    <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
    <arm_group_label>Azilsartan Medoxomil 40 mg QD</arm_group_label>
    <other_name>TAK-491</other_name>
    <other_name>Edarbi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil</intervention_name>
    <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
    <arm_group_label>Azilsartan Medoxomil 80 mg QD</arm_group_label>
    <other_name>TAK-491</other_name>
    <other_name>Edarbi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
    <arm_group_label>Valsartan 320 mg QD</arm_group_label>
    <other_name>Diovan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan</intervention_name>
    <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
    <arm_group_label>Olmesartan 40 mg QD</arm_group_label>
    <other_name>Benicar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo, orally, once daily for up to six weeks.</description>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Essential hypertension (sitting systolic blood pressure between 150 and 180 mm Hg,
             inclusive, at Day -1 and 24-hour mean systolic blood pressure between 130 and 170 mm
             Hg, inclusive, at Day 1).

          2. Capable of understanding and complying with protocol requirements.

          3. Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout
             the duration of the study

          4. Clinical laboratory evaluations within the reference range for the testing laboratory
             or the results are deemed not clinically significant for inclusion into this study by
             the investigator.

          5. Willing to discontinue current antihypertensive medications at Screening Day 21
             visit. If the participant is on amlodipine prior to Screening, the participant is
             willing to discontinue this medication at Screening Day -28.

        Exclusion Criteria:

          1. Sitting diastolic blood pressure greater than 114 mm Hg at Day -1 (day prior to
             Randomization).

          2. Baseline 24-hour ambulatory blood pressure monitor reading of insufficient quality.

          3. Taking or expected to take an excluded medication as described in the Excluded
             Medications.

          4. Hypersensitive to angiotensin II receptor blockers.

          5. History of myocardial infarction, heart failure, unstable angina, coronary artery
             bypass graft, percutaneous coronary intervention, hypertensive encephalopathy,
             cerebrovascular accident, or transient ischemic attack.

          6. Clinically significant cardiac conduction defects.

          7. Hemodynamically significant left ventricular outflow obstruction due to aortic
             valvular disease.

          8. Secondary hypertension of any etiology.

          9. Noncompliant (less than 70% or greater than 130%) with study medication during run-in
             period.

         10. Moderate to severe renal dysfunction or disease.

         11. Known or suspected unilateral or bilateral renal artery stenosis.

         12. History of drug or alcohol abuse within the past 2 years.

         13. Previous history of cancer that has not been in remission for at least 5 years prior
             to the first dose of study drug. (This criterion does not apply to those participants
             with basal cell or stage I squamous cell carcinoma of the skin).

         14. Type 1 or poorly-controlled type 2 diabetes mellitus (glycosylate hemoglobin greater
             than 8.0%) at Screening.

         15. Hyperkalemia as defined by the central laboratory normal reference range at
             Screening.

         16. Alanine aminotransferase level of greater than 2.5 times the upper limit of normal,
             active liver disease, or jaundice at Screening.

         17. Upper arm circumference less than 24 cm or greater than 42 cm.

         18. Works night (3rd) shift (defined as 11 PM [2300] to 7 AM [0700]).

         19. Unwilling or unable to comply with the protocol or scheduled appointments.

         20. Currently is participating in another investigational study or has participated in an
             investigational study within 30 days prior to Randomization.

         21. Any other serious disease or condition at Screening or Randomization that would
             compromise participant's safety, might affect life expectancy, or make it difficult
             to successfully manage and follow the subject according to the protocol.

         22. Has been randomized in a previous azilsartan medoxomil study.

         23. Is required to take or continues taking any disallowed medication, prescription
             medication, herbal treatment or over-the counter medication that may interfere with
             evaluation of the study medication.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Executive Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda Global Research &amp; Development Center, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Alabaster</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ozark</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Green Valley</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Dimas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Fransisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belleville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vernon Hills</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwood</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Margate</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carlos Paz</city>
        <state>Córdoba</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guaymayen</city>
        <state>Mendoza</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bahía Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berazategui</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haedo Pcia. de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jujuy</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ramos Mejía Pcia. de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel de Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiaenia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joildille</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sorocava</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>León</city>
        <state>Guanajuato</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <state>Jalapa</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xalapa</city>
        <state>Veracruz</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Querètaro</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosí</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cusco</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huaura</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ica</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trujillo</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguas Buenas</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carolina</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jardines de Loiza</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orocovis</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
  </location_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=68E3872B-7993-4087-8929-05B4E4E0E6D2&amp;FileTypeCode=EDARBIPI</url>
    <description>EDARBI Package Insert</description>
  </link>
  <results_reference>
    <citation>White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar;57(3):413-20. Epub 2011 Jan 31.</citation>
    <PMID>21282560</PMID>
  </results_reference>
  <verification_date>March 2011</verification_date>
  <lastchanged_date>March 24, 2011</lastchanged_date>
  <firstreceived_date>June 10, 2008</firstreceived_date>
  <firstreceived_results_date>March 24, 2011</firstreceived_results_date>
  <responsible_party>
    <name_title>Sr. VP, Clinical Science</name_title>
    <organization>Takeda Global Research &amp; Development Center, Inc.</organization>
  </responsible_party>
  <keyword>Essential Hypertension</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>High Blood Pressure</keyword>
  <keyword>Drug Therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan medoxomil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants enrolled at 141 investigative sites in  Guatemala, Mexico, Peru, Puerto Rico and the United States from 02 April 2008 to 19 August 2009.</recruitment_details>
      <pre_assignment_details>Participants with essential hypertension were enrolled in one of five, once-daily (QD) treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="P2">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="P3">
          <title>Valsartan 320 mg QD</title>
          <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="P4">
          <title>Olmesartan 40 mg QD</title>
          <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="P5">
          <title>Placebo QD</title>
          <description>Matching placebo, orally, once daily for up to six weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="280">Randomized participants only.</participants>
                <participants group_id="P2" count="285">Randomized participants only. One participant treated but not randomized and is not included.</participants>
                <participants group_id="P3" count="282">Randomized participants only.</participants>
                <participants group_id="P4" count="290">Randomized participants only.</participants>
                <participants group_id="P5" count="154">Randomized participants only.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="255"/>
                <participants group_id="P3" count="254"/>
                <participants group_id="P4" count="268"/>
                <participants group_id="P5" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Unavailability</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Error</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="B2">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="B3">
          <title>Valsartan 320 mg QD</title>
          <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="B4">
          <title>Olmesartan 40 mg QD</title>
          <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="B5">
          <title>Placebo QD</title>
          <description>Matching placebo, orally, once daily for up to six weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="280"/>
                <measurement group_id="B2" value="285"/>
                <measurement group_id="B3" value="282"/>
                <measurement group_id="B4" value="290"/>
                <measurement group_id="B5" value="154"/>
                <measurement group_id="B6" value="1291"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;45 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="56"/>
                <measurement group_id="B4" value="39"/>
                <measurement group_id="B5" value="20"/>
                <measurement group_id="B6" value="194"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 45 and 64 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="170"/>
                <measurement group_id="B2" value="184"/>
                <measurement group_id="B3" value="178"/>
                <measurement group_id="B4" value="185"/>
                <measurement group_id="B5" value="98"/>
                <measurement group_id="B6" value="815"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>≥65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="63"/>
                <measurement group_id="B3" value="48"/>
                <measurement group_id="B4" value="66"/>
                <measurement group_id="B5" value="36"/>
                <measurement group_id="B6" value="282"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="133"/>
                <measurement group_id="B2" value="134"/>
                <measurement group_id="B3" value="130"/>
                <measurement group_id="B4" value="131"/>
                <measurement group_id="B5" value="64"/>
                <measurement group_id="B6" value="592"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="147"/>
                <measurement group_id="B2" value="151"/>
                <measurement group_id="B3" value="152"/>
                <measurement group_id="B4" value="159"/>
                <measurement group_id="B5" value="90"/>
                <measurement group_id="B6" value="699"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-13.42" spread="0.690"/>
                  <measurement group_id="O2" value="-14.53" spread="0.702"/>
                  <measurement group_id="O3" value="-10.22" spread="0.696"/>
                  <measurement group_id="O4" value="-11.99" spread="0.666"/>
                  <measurement group_id="O5" value="-0.25" spread="0.917"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.54</ci_lower_limit>
            <ci_upper_limit>-12.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.41</ci_lower_limit>
            <ci_upper_limit>-10.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.009</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.44</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.25</ci_lower_limit>
            <ci_upper_limit>-2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.136</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.31</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.12</ci_lower_limit>
            <ci_upper_limit>-1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.</title>
        <description>The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="269"/>
                  <measurement group_id="O2" value="270"/>
                  <measurement group_id="O3" value="271"/>
                  <measurement group_id="O4" value="283"/>
                  <measurement group_id="O5" value="148"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.</title>
            <description>The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-16.38" spread="0.959"/>
                  <measurement group_id="O2" value="-16.74" spread="0.957"/>
                  <measurement group_id="O3" value="-11.31" spread="0.955"/>
                  <measurement group_id="O4" value="-13.20" spread="0.935"/>
                  <measurement group_id="O5" value="-1.83" spread="1.293"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.07</ci_lower_limit>
            <ci_upper_limit>-11.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.71</ci_lower_limit>
            <ci_upper_limit>-11.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.008</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.17</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.09</ci_lower_limit>
            <ci_upper_limit>-2.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.018</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.81</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented. Overall 0.05 level of significance for multiple comparisons was controlled using stepwise testing procedure.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.73</ci_lower_limit>
            <ci_upper_limit>-2.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.65" spread="0.472"/>
                  <measurement group_id="O2" value="-9.43" spread="0.480"/>
                  <measurement group_id="O3" value="-7.09" spread="0.476"/>
                  <measurement group_id="O4" value="-7.74" spread="0.456"/>
                  <measurement group_id="O5" value="-0.07" spread="0.627"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.91</ci_lower_limit>
            <ci_upper_limit>-7.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.12</ci_lower_limit>
            <ci_upper_limit>-7.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.011</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.99</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.67</ci_lower_limit>
            <ci_upper_limit>-1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.166</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.19</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.020</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.88</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure</title>
        <description>The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="269"/>
                  <measurement group_id="O2" value="270"/>
                  <measurement group_id="O3" value="271"/>
                  <measurement group_id="O4" value="283"/>
                  <measurement group_id="O5" value="148"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure</title>
            <description>The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-6.97" spread="0.552"/>
                  <measurement group_id="O2" value="-8.27" spread="0.551"/>
                  <measurement group_id="O3" value="-5.11" spread="0.550"/>
                  <measurement group_id="O4" value="-6.10" spread="0.538"/>
                  <measurement group_id="O5" value="-0.76" spread="0.744"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.33</ci_lower_limit>
            <ci_upper_limit>-5.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.03</ci_lower_limit>
            <ci_upper_limit>-4.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.005</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.69</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.69</ci_lower_limit>
            <ci_upper_limit>-1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.257</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.39</ci_lower_limit>
            <ci_upper_limit>0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.017</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.39</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-13.73" spread="0.724"/>
                  <measurement group_id="O2" value="-15.02" spread="0.736"/>
                  <measurement group_id="O3" value="-10.26" spread="0.730"/>
                  <measurement group_id="O4" value="-12.16" spread="0.699"/>
                  <measurement group_id="O5" value="-0.11" spread="0.963"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.30</ci_lower_limit>
            <ci_upper_limit>-12.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.99</ci_lower_limit>
            <ci_upper_limit>-11.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.005</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.85</ci_lower_limit>
            <ci_upper_limit>-0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.80</ci_lower_limit>
            <ci_upper_limit>-2.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.119</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.55</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.49</ci_lower_limit>
            <ci_upper_limit>-1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.96" spread="0.510"/>
                  <measurement group_id="O2" value="-9.80" spread="0.518"/>
                  <measurement group_id="O3" value="-7.23" spread="0.514"/>
                  <measurement group_id="O4" value="-7.82" spread="0.492"/>
                  <measurement group_id="O5" value="0.01" spread="0.677"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.48</ci_lower_limit>
            <ci_upper_limit>-8.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.63</ci_lower_limit>
            <ci_upper_limit>-7.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.006</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.39</ci_lower_limit>
            <ci_upper_limit>-0.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.00</ci_lower_limit>
            <ci_upper_limit>-1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.107</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.53</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.017</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.15</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-12.28" spread="0.778"/>
                  <measurement group_id="O2" value="-13.32" spread="0.792"/>
                  <measurement group_id="O3" value="-9.66" spread="0.784"/>
                  <measurement group_id="O4" value="-11.90" spread="0.752"/>
                  <measurement group_id="O5" value="-0.31" spread="1.035"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.56</ci_lower_limit>
            <ci_upper_limit>-10.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.51</ci_lower_limit>
            <ci_upper_limit>-9.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.194</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.56</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.84</ci_lower_limit>
            <ci_upper_limit>-1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.720</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.51</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.018</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.79</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-7.65" spread="0.540"/>
                  <measurement group_id="O2" value="-8.54" spread="0.550"/>
                  <measurement group_id="O3" value="-6.26" spread="0.544"/>
                  <measurement group_id="O4" value="-7.82" spread="0.522"/>
                  <measurement group_id="O5" value="0.10" spread="0.718"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.42</ci_lower_limit>
            <ci_upper_limit>-6.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.52</ci_lower_limit>
            <ci_upper_limit>-5.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.341</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.21</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.003</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>-0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.821</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.30</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.071</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-14.03" spread="0.764"/>
                  <measurement group_id="O2" value="-15.55" spread="0.777"/>
                  <measurement group_id="O3" value="-10.44" spread="0.770"/>
                  <measurement group_id="O4" value="-12.23" spread="0.738"/>
                  <measurement group_id="O5" value="-0.10" spread="1.016"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.96</ci_lower_limit>
            <ci_upper_limit>-12.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.42</ci_lower_limit>
            <ci_upper_limit>-11.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.002</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.42</ci_lower_limit>
            <ci_upper_limit>-1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.26</ci_lower_limit>
            <ci_upper_limit>-2.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.091</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.88</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.72</ci_lower_limit>
            <ci_upper_limit>-1.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="237"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-9.16" spread="0.542"/>
                  <measurement group_id="O2" value="-10.13" spread="0.551"/>
                  <measurement group_id="O3" value="-7.42" spread="0.547"/>
                  <measurement group_id="O4" value="-7.82" spread="0.524"/>
                  <measurement group_id="O5" value="0.01" spread="0.721"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.92</ci_lower_limit>
            <ci_upper_limit>-8.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.94</ci_lower_limit>
            <ci_upper_limit>-7.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.002</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.81</ci_lower_limit>
            <ci_upper_limit>-0.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.24</ci_lower_limit>
            <ci_upper_limit>-1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.076</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.82</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.024</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.25</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="236"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-12.46" spread="0.860"/>
                  <measurement group_id="O2" value="-13.38" spread="0.873"/>
                  <measurement group_id="O3" value="-9.14" spread="0.865"/>
                  <measurement group_id="O4" value="-11.65" spread="0.829"/>
                  <measurement group_id="O5" value="-0.55" spread="1.142"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.66</ci_lower_limit>
            <ci_upper_limit>-10.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-11.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.72</ci_lower_limit>
            <ci_upper_limit>-9.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.149</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.10</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.65</ci_lower_limit>
            <ci_upper_limit>-1.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.494</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.16</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.007</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.72</ci_lower_limit>
            <ci_upper_limit>-0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
        <description>The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="236"/>
                  <measurement group_id="O2" value="229"/>
                  <measurement group_id="O3" value="234"/>
                  <measurement group_id="O4" value="254"/>
                  <measurement group_id="O5" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.</title>
            <description>The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
            <units>mmHg</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-8.69" spread="0.648"/>
                  <measurement group_id="O2" value="-8.61" spread="0.657"/>
                  <measurement group_id="O3" value="-6.22" spread="0.651"/>
                  <measurement group_id="O4" value="-8.25" spread="0.624"/>
                  <measurement group_id="O5" value="-0.69" spread="0.859"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.03</ci_lower_limit>
            <ci_upper_limit>-5.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.10</ci_lower_limit>
            <ci_upper_limit>-5.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.691</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.14</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.010</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.20</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.625</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.20</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.008</p_value>
            <p_value_desc>Postbaseline P-value was from ANCOVA with treatment as a factor and baseline value as a covariate. Unadjusted p-value was presented.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.27</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg</title>
        <description>Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="269"/>
                  <measurement group_id="O2" value="270"/>
                  <measurement group_id="O3" value="271"/>
                  <measurement group_id="O4" value="283"/>
                  <measurement group_id="O5" value="148"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as &lt; 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg</title>
            <description>Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56.5"/>
                  <measurement group_id="O2" value="57.8"/>
                  <measurement group_id="O3" value="48.7"/>
                  <measurement group_id="O4" value="48.8"/>
                  <measurement group_id="O5" value="22.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.15</ci_lower_limit>
            <ci_upper_limit>7.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.94</ci_lower_limit>
            <ci_upper_limit>7.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.032</p_value>
            <p_value_desc>P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.029</p_value>
            <p_value_desc>P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.080</p_value>
            <p_value_desc>P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.071</p_value>
            <p_value_desc>P-value for response criteria for systolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg</title>
        <description>Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="269"/>
                  <measurement group_id="O2" value="270"/>
                  <measurement group_id="O3" value="271"/>
                  <measurement group_id="O4" value="283"/>
                  <measurement group_id="O5" value="148"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as &lt; 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg</title>
            <description>Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68.8"/>
                  <measurement group_id="O2" value="71.1"/>
                  <measurement group_id="O3" value="63.8"/>
                  <measurement group_id="O4" value="68.2"/>
                  <measurement group_id="O5" value="43.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>5.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>4.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.306</p_value>
            <p_value_desc>P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.132</p_value>
            <p_value_desc>P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.695</p_value>
            <p_value_desc>P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.381</p_value>
            <p_value_desc>P-value for response criteria for diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic diastolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response</title>
        <description>Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.</description>
        <time_frame>Baseline and Week 6.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full analysis set with last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg QD</title>
            <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O4">
            <title>Olmesartan 40 mg QD</title>
            <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
          </group>
          <group group_id="O5">
            <title>Placebo QD</title>
            <description>Matching placebo, orally, once daily for up to six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="269"/>
                  <measurement group_id="O2" value="270"/>
                  <measurement group_id="O3" value="271"/>
                  <measurement group_id="O4" value="283"/>
                  <measurement group_id="O5" value="148"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response</title>
            <description>Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements.</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="49.1"/>
                  <measurement group_id="O2" value="52.6"/>
                  <measurement group_id="O3" value="43.9"/>
                  <measurement group_id="O4" value="44.5"/>
                  <measurement group_id="O5" value="18.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.20</ci_lower_limit>
            <ci_upper_limit>8.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.73</ci_lower_limit>
            <ci_upper_limit>7.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.056</p_value>
            <p_value_desc>P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.036</p_value>
            <p_value_desc>P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>2.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.317</p_value>
            <p_value_desc>P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.234</p_value>
            <p_value_desc>P-value for joint response criteria for systolic blood pressure and diastolic blood pressure was from a logistic regression with treatment as a factor and baseline clinic systolic blood pressure as a covariate. The unadjusted p-value was presented.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="E2">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="E3">
          <title>Valsartan 320 mg QD</title>
          <description>Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="E4">
          <title>Olmesartan 40 mg QD</title>
          <description>Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo QD</title>
          <description>Matching placebo, orally, once daily for up to six weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="284"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="277"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="290"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
